Cipla Ltd's Q3FY25 Quarter Results
- 30 Jan 2025
Result Summary
- Cipla Ltd reported a 0.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 7.5%.
- Its expenses for the quarter were down by 1.4% QoQ and up 5.1% YoY.
- The net profit increased 20.7% QoQ and increased 47.4% YoY.
- The earnings per share (EPS) of Cipla Ltd - at - during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 7294.58 | 7241.63 | 6788.44 | 0.7% | 7.5% |
Total Expenses | 5378.49 | 5452.57 | 5119.81 | -1.4% | 5.1% |
Profit Before Tax | 1916.09 | 1789.06 | 1473.81 | 7.1% | 30.0% |
Tax | 332.37 | 483.04 | 405.30 | -31.2% | -18.0% |
Profit After Tax | 1574.59 | 1305.01 | 1068.41 | 20.7% | 47.4% |
Earnings Per Share | 0.00 | 16.10 | 13.10 | -100.0% | -100.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Cipla Ltd is a leading pharmaceutical company headquartered in India. The company is renowned for manufacturing and marketing a wide range of pharmaceutical products across various therapeutic segments. Cipla's portfolio includes drugs for respiratory diseases, cardiovascular conditions, diabetes, and other critical health areas. The company operates both domestically and internationally, with a significant presence in various global markets. Recent developments for Cipla may include expansion plans, regulatory approvals for new drugs, and strategic partnerships, although the specifics are not detailed in the provided data.
Revenue
In the third quarter of fiscal year 2025 (Q3FY25), Cipla Ltd reported total income of ₹7294.58 crores, marking a 0.7% increase compared to the previous quarter (Q2FY25) where total income was ₹7241.63 crores. Year-over-year (YoY), the total income showed a 7.5% growth from ₹6788.44 crores reported in the third quarter of fiscal year 2024 (Q3FY24). This indicates a steady increase in revenue over the past year, reflecting Cipla's ability to enhance its sales and possibly expand its market reach. The consistent rise in revenue highlights the company's operational efficacy in maintaining a growth trajectory in its financial performance.
Profitability
Cipla Ltd's profitability metrics for the third quarter of fiscal year 2025 show a positive trend. The company recorded a profit before tax of ₹1916.09 crores, which represents a 7.1% increase from the previous quarter's figure of ₹1789.06 crores and a substantial 30% rise from the ₹1473.81 crores reported in Q3FY24. The profit after tax for Q3FY25 was ₹1574.59 crores, displaying a significant quarter-over-quarter growth of 20.7% from ₹1305.01 crores in Q2FY25, and a remarkable 47.4% increase from ₹1068.41 crores in Q3FY24. The tax expenses for the quarter decreased by 31.2% on a QoQ basis and by 18% YoY, contributing to the improved net profitability. This financial performance underscores Cipla's effective cost management and its strategic initiatives to enhance profitability.
Operating Metrics
Cipla Ltd's operating performance in Q3FY25 reflects a reduction in total expenses, which amounted to ₹5378.49 crores, down by 1.4% from ₹5452.57 crores in Q2FY25. This indicates a successful effort in managing operational costs. Compared to the same quarter in the previous year, total expenses increased by 5.1% from ₹5119.81 crores, which may correlate with the company's growth in revenue and expanded operations. An anomaly in the data is the reported earnings per share (EPS), which is shown as 0.00 for Q3FY25, despite a profitable quarter, contrasting with ₹16.10 in Q2FY25 and ₹13.10 in Q3FY24. This discrepancy might require further investigation into accounting practices or reporting errors. Overall, Cipla's operating metrics demonstrate efficient cost control and robust financial management practices.
